CDK 4/6 inhibitors combined with radiotherapy: A review of literature
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and abemaciclib were granted approval by the European Medicines Agency (EMA) between 2017 and 2018. They are currently prescribed in combination with hormone therapy to treat hormone receptor positive, HER2 negative...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Clinical and Translational Radiation Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630820300999 |